-
公开(公告)号：US20060122374A1
公开(公告)日：2006-06-08
申请号：US10503836
申请日：2003-02-07
申请人： Peter Mertins , Iihan Celik , Oliver Elaker , Darrell Sleep , Joanna Hay , Hans-Peter Hanger
发明人： Peter Mertins , Iihan Celik , Oliver Elaker , Darrell Sleep , Joanna Hay , Hans-Peter Hanger
IPC分类号： C07K14/765 , A61K38/37
CPC分类号： A61K38/39 , A01K2217/05 , A61K9/0019 , A61K31/7088 , A61K38/00 , A61K39/00 , A61K39/0005 , A61K47/643 , A61K48/00 , A61K2039/53 , C07K14/005 , C07K14/47 , C07K14/765 , C07K14/78 , C07K14/8114 , C07K2319/00 , C07K2319/31 , C12N15/62 , C12N2740/16122 , C12Y301/26003
摘要： The invention relates to proteins comprising angiogenesis inhibiting peptides, such as endostatin peptides (including, but not limited to, fragments and variants thereof), which exhibit anti-retroviral activity, fused or conjugated to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acuds, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for inhibiting proliferation of vascular endothelial cells and tumor aniogenesis induced cell fusion. The invention further relates to compositions and methods preventing growth of, or promoting regression of, primary tumors and metastases; and for treating cancer, diabetic retinophathy, progressive macular degeneration or rheumatoid arthritis.
摘要翻译： 本发明涉及包含血管生成抑制肽（例如内皮抑素肽（包括但不限于其片段和变体））的蛋白质，其表现出与白蛋白融合或缀合的抗逆转录病毒活性（包括但不限于片段或变体 的白蛋白）。 这些融合蛋白在本文中统称为“本发明的白蛋白融合蛋白”。 这些融合蛋白在本文中统称为“本发明的白蛋白融合蛋白”。 这些融合蛋白在溶液中表现出延长的保质期和/或延长或治疗活性。 本发明包括治疗性白蛋白融合蛋白，组合物，药物组合物，制剂和试剂盒。 本发明还包括编码本发明的白蛋白融合蛋白的核酸分子以及含有这些核酸的载体，用这些核酸和载体转化的宿主细胞，以及使用这些核酸制备本发明的白蛋白融合蛋白的方法 ，载体和/或宿主细胞。 本发明还涉及抑制血管内皮细胞增殖和肿瘤发生生成诱导的细胞融合的组合物和方法。 本发明还涉及预防原发性肿瘤和转移瘤的生长或促进消退的组合物和方法; 并用于治疗癌症，糖尿病性视网膜病变，进行性黄斑变性或类风湿性关节炎。
-
公开(公告)号：US20120263747A1
公开(公告)日：2012-10-18
申请号：US13285727
申请日：2011-10-31
申请人： Peter Mertins , Ilhan Celik , Oliver Kisker , Darrell Sleep , Joanna Hay , Hans-Peter Hauser
发明人： Peter Mertins , Ilhan Celik , Oliver Kisker , Darrell Sleep , Joanna Hay , Hans-Peter Hauser
IPC分类号： C07K19/00 , A61P9/10 , A61P9/00 , A61K39/385 , A61K48/00 , A61P37/04 , A61P29/00 , A61P19/02 , A61P17/06 , A61P27/02 , A61P1/00 , A61P17/00 , A61P17/02 , A61P1/04 , A61K38/38
CPC分类号： A61K38/39 , A01K2217/05 , A61K9/0019 , A61K31/7088 , A61K38/00 , A61K39/00 , A61K39/0005 , A61K47/643 , A61K48/00 , A61K2039/53 , C07K14/005 , C07K14/47 , C07K14/765 , C07K14/78 , C07K14/8114 , C07K2319/00 , C07K2319/31 , C12N15/62 , C12N2740/16122 , C12Y301/26003
摘要： The invention relates to proteins comprising angiogenesis inhibiting peptides, such as endostatin peptides (including, but not limited to, fragments and variants thereof), which exhibit anti-retroviral activity, fused or conjugated to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins are herein collectively referred to as ‘albumin fusion proteins of the invention.’ These fusion proteins are herein collectively referred to as ‘albumin fusion proteins of the invention.’ These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for inhibiting proliferation of vascular endothelial cells and tumor aniogenesis induced cell fusion. The invention further relates to compositions and methods preventing growth of, or promoting regression of, primary tumors and metastases; and for treating cancer, diabetic retinophathy, progressive macular degeneration or rheumatoid arthritis.
摘要翻译： 本发明涉及包含血管生成抑制肽（例如内皮抑素肽（包括但不限于其片段和变体））的蛋白质，其表现出与白蛋白融合或缀合的抗逆转录病毒活性（包括但不限于片段或变体 的白蛋白）。 这些融合蛋白在本文中统称为白蛋白融合蛋白。 这些融合蛋白在本文中统称为白蛋白融合蛋白。 这些融合蛋白在溶液中表现出延长的保质期和/或延长或治疗活性。 本发明包括治疗性白蛋白融合蛋白，组合物，药物组合物，制剂和试剂盒。 本发明还包括编码本发明的白蛋白融合蛋白的核酸分子以及含有这些核酸的载体，用这些核酸和载体转化的宿主细胞，以及使用这些核酸制备本发明的白蛋白融合蛋白的方法 ，载体和/或宿主细胞。 本发明还涉及抑制血管内皮细胞增殖和肿瘤发生生成诱导的细胞融合的组合物和方法。 本发明还涉及预防原发性肿瘤和转移瘤的生长或促进消退的组合物和方法; 并用于治疗癌症，糖尿病性视网膜病变，进行性黄斑变性或类风湿性关节炎。
-
公开(公告)号：US20120059155A1
公开(公告)日：2012-03-08
申请号：US13319019
申请日：2010-05-07
申请人： Leslie Robert Evans , Miranda Hughes , Joanna Hay , Darrell Sleep , David John Tooth , Neil Dodsworth , Malcolm John Saxton , Joanne Patricia Waters , Steven Athwal
发明人： Leslie Robert Evans , Miranda Hughes , Joanna Hay , Darrell Sleep , David John Tooth , Neil Dodsworth , Malcolm John Saxton , Joanne Patricia Waters , Steven Athwal
CPC分类号： C07K16/00 , C07K16/44 , C07K2317/41 , C07K2317/622 , C07K2319/31
摘要： A method for producing antibodies in fungal host cells is provided where the produced antibodies has a low degree of glycosylation.
摘要翻译： 提供了一种在真菌宿主细胞中产生抗体的方法，其中产生的抗体具有低糖基化程度。
-
公开(公告)号：US20100222267A1
公开(公告)日：2010-09-02
申请号：US12664454
申请日：2008-06-13
摘要： The present invention provides a recombinant protein comprising the sequence of a transferrin mutant, wherein Ser415 is mutated to an amino acid which does not allow glycosylation at Asn413 and/or wherein Thr613 is mutated to an amino acid which does not allow glycosylation as Asn611. It also provides polynucleotides encoding the same and methods of making and using said recombinant protein.
摘要翻译： 本发明提供了包含转铁蛋白突变体序列的重组蛋白，其中Ser415突变为不允许Asn413上的糖基化和/或其中Thr613突变为不允许糖基化作为Asn611的氨基酸的氨基酸。 它还提供了编码其的多核苷酸以及制备和使用所述重组蛋白的方法。
-
公开(公告)号：US20090175893A1
公开(公告)日：2009-07-09
申请号：US12358815
申请日：2009-01-23
申请人： Peter Mertins , Ilhan Celik , Oliver Kisker , Darrell Sleep , Joanna Hay , Hans-Peter Hauser
发明人： Peter Mertins , Ilhan Celik , Oliver Kisker , Darrell Sleep , Joanna Hay , Hans-Peter Hauser
CPC分类号： A61K38/39 , A01K2217/05 , A61K9/0019 , A61K31/7088 , A61K38/00 , A61K39/00 , A61K39/0005 , A61K47/643 , A61K48/00 , A61K2039/53 , C07K14/005 , C07K14/47 , C07K14/765 , C07K14/78 , C07K14/8114 , C07K2319/00 , C07K2319/31 , C12N15/62 , C12N2740/16122 , C12Y301/26003
摘要： The invention relates to proteins comprising angiogenesis inhibiting peptides, such as endostatin peptides (including, but not limited to, fragments and variants thereof), which exhibit anti-retroviral activity, fused or conjugated to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for inhibiting proliferation of vascular endothelial cells and tumor angiogenesis induced cell fusion. The invention further relates to compositions and methods preventing growth of, or promoting regression of, primary tumors and metastases; and for treating cancer, diabetic retinopathy, progressive macular degeneration or rheumatoid arthritis.
摘要翻译： 本发明涉及包含血管生成抑制肽（例如内皮抑素肽（包括但不限于其片段和变体））的蛋白质，其表现出与白蛋白融合或缀合的抗逆转录病毒活性（包括但不限于片段或变体 的白蛋白）。 这些融合蛋白在本文中统称为“本发明的白蛋白融合蛋白”。 这些融合蛋白在本文中统称为“本发明的白蛋白融合蛋白”。 这些融合蛋白在溶液中表现出延长的保质期和/或延长或治疗活性。 本发明包括治疗性白蛋白融合蛋白，组合物，药物组合物，制剂和试剂盒。 本发明还包括编码本发明的白蛋白融合蛋白的核酸分子以及含有这些核酸的载体，用这些核酸和载体转化的宿主细胞，以及使用这些核酸制备本发明的白蛋白融合蛋白的方法 ，载体和/或宿主细胞。 本发明还涉及抑制血管内皮细胞增殖和肿瘤血管生成诱导的细胞融合的组合物和方法。 本发明还涉及预防原发性肿瘤和转移瘤的生长或促进消退的组合物和方法; 并用于治疗癌症，糖尿病性视网膜病变，进行性黄斑变性或类风湿性关节炎。
-
-
-
-
搜索结果
5 条记录 (耗时 0.016 秒)
